How Many People Might Lose Medicaid?

The pharmacy industry sees at least five changes

Three Healthcare Organizations Join Forces to Save Lives

Significant improvement in glycemic control among participants demonstrates the substantial impact that pharmacies partnered with charitable medication distributors such as the Dispensary of Hope can have on individuals with insulin-treated T2D

Recent federal legislative and regulatory updates in managed care pharmacy have prioritized topics ranging from expedited access to novel therapeutics to the health disparities and equity concerns affecting patient populations nationwide, but progress on these developments will depend on the impact of the midterm elections

Today’s release of new 2020 Census data provides population counts of nearly 1,500 race and ethnicity groups and American Indian and Alaska Native (AIAN) tribes and villages.

An opportunity for charitable pharmacies to collaborate with oncology practices for non-oncology medications during and after treatment.

APPLICATIONS ARE OPEN! – Letters of Intent due 9/15/23

This study represents a rigorous, multi-state evaluation that highlights the impact of a charitable medication access program on hospital utilization for the medically under-served population.

Good Pill will provide direct access to hundreds of life-saving medications and save families $150+/month on healthcare cost

‘Unbelievably good price’: KC-area pharmacy dispenses bargain medicine — and hope Go to article

We estimate that if the PHE expires in April 2023, 18.0 million people will lose Medicaid coverage in the following…

A Fireside Chat with AAM Chair, Christine Baeder and Mark Cuban, Entrepreneur and Cost Plus founder

NOVA ScriptsCentral is excited to collaborate with the American Pharmacist Association to launch the “NOVA ScriptsCentral & American Pharmacist Association Safety-Net Health Equity Fellowship”.

Once the continuous enrollment ends, it is estimated between 5 -14 million individuals will be affected

NABP Associate Executive Director Josh Bolin on DSCSA compliance prior to FDA moving compliance deadline.